Monday, 8 June 2026
Victoria House, Bloomsbury, London
Over the past year, the UK life sciences sector has been at a cross roads, with companies questioning their investment plans in light of reimbursement challenges and tariff uncertainty. The UK Government published an ambitious Industrial Strategy and Life Sciences Sector Plan with a vision for the UK leading Europe by 2030 and being third in the world by 2035. How will it achieve this?
PING 2026 arrives at precisely the right moment. In collaboration with the Ethical Medicines Industry Group (EMIG), this year’s conference will provide an overview of the Sector Plan, how the MHRA is looking to lead as an innovative regulator, the unique opportunities within the NHS and the £600m Health Data Research Service, a spotlight on cell and gene therapies, the commitment to manufacturing capability, and opportunities for export. A key question is: what does industry think of this?
Whether you're at early stage R&D or ecosystems around accelerators and incubators or involved in the manufacture or supply of finished pharma product, we hope you enjoy the personalised and friendly networking with leaders in a lovely community for which PING has become renowned. This year for the first time PING is in London - in a stunning listed building that George Freeman MP has called "an inspiring London Hub for Life Science innovation". You will have the chance to have a tour of Victoria House and be astounded at its transformation into 300,000 square foot of lab and office space, enjoy drinks in the impressive atrium and if you book early then there is dinner and entertainment at The Cabaret Club to cap a wonderful day - with more chance to enjoy the unique PING Conference feel and have in depth conversations in an unforgettable setting.
Conference themes
Explore the Conference themes below:
Speakers
Delegates will hear from the people shaping the future of UK life sciences, with speakers from leading institutions and industry sharing their insights. They will also hear the response from industry leaders on what the plans mean in practice, with plenty of opportunities for everyone in the room to have their say.
|
Bill Morgan Senior Partner at Newmarket Strategy (and Former Health Policy Special Adviser at Number 10 Downing Street) |
James Duboff Strategic Partnerships Director from Genomics England |
Ivana Poparic Head of Life Sciences Cluster Development at MedCity |
|
Matthew Durdy Chief Executive Officer of the Cell and Gene Therapy Catapult |
Rikesh Patel Senior Trade Manager in Life Sciences at London and Partners |
Leslie Galloway Chair of the Ethical Medicines Industry Group (EMIG) |
|
Chris Davison Chief Executive Officer, Custom Pharma |
Miranda Knaggs Corporate Development Director at Pioneer Group |
The venue
"London's Hub for Life Sciences innovation" - George Freeman, UK politician, UK Trade Envoy, and former UK Minister for Science & Technology
For our 17th PING Conference, we are excited to welcome delegates to Victoria House, a landmark newly repurposed as one of London’s most significant life sciences hubs.
Victoria House is a Grade II listed building in the heart of Bloomsbury, formerly the Liverpool Victoria head office and now reimagined as a world-class science facility, operated by Pioneer Group.
Personalised, high-impact networking
More than a conference, PING is a community of people from across the pharmaceutical and life sciences ecosystem.
Delegates consistently feedback that the personalised networking, warm introductions and high-value discussions at PING are what keep our community returning year after year.
Whether it’s your first time or your 17th, you will enjoy the buzz of the personalised networking opportunities that are synonymous with PING.
Details
Date: Monday, 8 June 2026
Address: Victoria House, Bloomsbury Square, London, WC1B 4DA
Timings:
- 12:00 pm - 1:30 pm - Lunch, networking & tours
Lunch and drinks are kindly sponsored by Hertfordshire Growth Board. Hertfordshire Growth Board sees life sciences as central to the UK’s future - anchored in the county’s unique strengths: world-class pharma R&D, Europe’s biggest cell & gene therapy cluster, and a dynamic network of innovators transforming healthcare and powering sustainable growth.
- 1:30 pm - 5:30 pm - Presentations & audience discussion
- 5:30 pm - 6:45 pm - Networking drinks in the atrium
- 6:45 pm - 9:30 pm - Dinner and entertainment at The Cabaret Club (for those who have paid - please note there is a limited number of places)
Pricing
Early bird - Available until Friday, 10 April 2026
Full conference including dinner and entertainment: £280 +VAT
Day delegate rate (for delegates unable to stay for the evening programme): £170 +VAT
Standard rate - Available from Saturday, 11 April 2026
Full conference including dinner and entertainment: £340 +VAT
Day delegate rate (for delegates unable to stay for the evening programme): £210 +VAT
Discover more
- Articles
Your business is considering decentralised manufacturing for a product - what are the steps you need to take?
As discussed in our previous article, the UK is the first country to have implemented a framework to allow Point of Care (POC) and Modular Manufacturing (MM), together known as Decentralised Manufacturing (DM). This is a really exciting step, particularly for the area of personalised medicines, but there are certain considerations and mandatory steps for businesses to take before they implement DM processes.
